Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARENA PHARMACEUTICALS, INC.

(ARNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/20/2021 10/21/2021 10/22/2021 10/25/2021 10/26/2021 Date
61.55(c) 61.68(c) 60.35(c) 58.65(c) 56.94 Last
250 343 318 409 392 862 370 974 1 166 355 Volume
+1.00% +0.21% -2.16% -2.82% -2.92% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 18,4 M - -
Net income 2021 -546 M - -
Net cash position 2021 709 M - -
P/E ratio 2021 -6,36x
Yield 2021 -
Sales 2022 27,4 M - -
Net income 2022 -567 M - -
Net cash position 2022 640 M - -
P/E ratio 2022 -6,52x
Yield 2022 -
Capitalization 3 478 M 3 478 M -
EV / Sales 2021 150x
EV / Sales 2022 104x
Nbr of Employees 363
Free-Float 99,7%
More Financials
Company
Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. The Company's clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five.... 
More about the company
Ratings of Arena Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ARENA PHARMACEUTICALS, INC.
10/22ARENA PHARMACEUTICALS : Reports inducement grants under nasdaq listing rule 5635(4)
AQ
10/21ARENA PHARMACEUTICALS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
10/14ARENA PHARMACEUTICALS : to Release Third Quarter 2021 Financial Results and Provide Corpor..
BU
09/20ARENA PHARMACEUTICALS : Reports inducement grants under nasdaq listing rule 5635(4)
AQ
09/17ARENA PHARMACEUTICALS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
09/02ARENA PHARMACEUTICALS : to Host Virtual R&D Investor Calls and Participate in Upcoming Sep..
BU
08/19ARENA PHARMACEUTICALS : Reports inducement grants under nasdaq listing rule 5635(4)
AQ
08/18ARENA PHARMACEUTICALS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
08/10ARENA PHARMACEUTICALS : Cantor Fitzgerald Adjusts Arena Pharmaceuticals' Price Target to $..
MT
08/06SECTOR UPDATE : Health Care Stocks Largely Struggle Friday
MT
08/06SECTOR UPDATE : Health Care Stocks Drifting Lower on Friday
MT
08/06ARENA PHARMACEUTICALS : Credit Suisse Lowers Arena Pharmaceuticals' PT to $98 from $102, N..
MT
08/05ARENA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
08/05ARENA PHARMACEUTICALS : Reports Second Quarter Financial Results and Key Program Updates
BU
08/05Arena Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June ..
CI
More news
News in other languages on ARENA PHARMACEUTICALS, INC.

- No features available -

More news
Analyst Recommendations on ARENA PHARMACEUTICALS, INC.
More recommendations
Chart ARENA PHARMACEUTICALS, INC.
Duration : Period :
Arena Pharmaceuticals, Inc. Technical Analysis Chart | ARNA | US0400476075 | MarketScreener
Technical analysis trends ARENA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 56,94 $
Average target price 95,80 $
Spread / Average Target 68,2%
EPS Revisions
Managers and Directors
Amit Dilip Munshi President, Chief Executive Officer & Director
Laurie D. Stelzer Chief Financial Officer & Executive Vice President
Garry Arthur Neil Chairman
Douglas A. Bakan Vice President-Technical Operations
Paul D. Streck Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ARENA PHARMACEUTICALS, INC.-23.66%3 582
MODERNA, INC.234.60%141 099
LONZA GROUP AG31.93%60 646
IQVIA HOLDINGS INC.43.58%49 145
SEAGEN INC.0.22%31 933
CELLTRION, INC.-38.02%25 328